volume 85, issue 2, P208-211 2008
DOI: 10.1038/clpt.2008.242
View full text
|
|
Share

Abstract: AbstractTargeted therapies are increasingly being incorporated into standard treatment regimens for cancer. Tyrosine kinase inhibitors represent one class of targeted agents, with eight drugs receiving approval for the treatment of cancer in recent years. Although they hold the promise of being more effective and less toxic to normal cells than conventional cytotoxic chemotherapy, tyrosine kinase inhibitors are associated with different adverse effects, sometimes severe, as well as wide pharmacokinetic variab…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
24
0

Publication Types

Select...

Relationship

0
0

Authors

Journals